Form 4: Telomir Pharmaceuticals CFO Michelle Yanez Reports Stock Option Grant

Michelle Yanez, CFO of Telomir Pharmaceuticals, reports the acquisition of incentive stock options.

Summary

• Michelle Yanez, the Chief Financial Officer of Telomir Pharmaceuticals, filed a Form 4 with the SEC.
• The report details the grant of incentive stock options to Yanez on August 27, 2024.
• Yanez acquired the right to buy 200,000 shares of Telomir Pharmaceuticals common stock at an exercise price of $5.02 per share.
• The options vest in four equal installments of 50,000 shares on February 26, 2025, August 26, 2025, February 26, 2026, and August 26, 2026.
• The options expire on August 27, 2034.
• Following the transaction, Yanez directly owns 200,000 derivative securities.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a routine disclosure of executive compensation.

Positives

• The grant of stock options aligns the CFO's interests with those of the shareholders.
• The vesting schedule incentivizes long-term performance.

Industry Context

Stock option grants are a common form of executive compensation in the pharmaceutical industry, aligning management's interests with shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the pharmaceutical industry.
• The size and vesting schedule of the grant would need to be compared to similar companies of comparable size and stage of development to determine if it is in line with industry norms.
• Companies like BioAge Labs and Unity Biotechnology also utilize stock options as part of their compensation strategy.

Stakeholder Impact

• The stock option grant could potentially impact shareholders by diluting ownership if the options are exercised.
• Employees may be impacted positively as the CFO's incentives are aligned with the company's success.

Key Dates